my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
27-06-2012: Prosensa has won the Emerging Star accolade at the European Mediscience Awards. The European Mediscience Awards is the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe recognising achievements in the life sciences industry.
Collecting the award, Dr.Giles Campion, Prosensa’s Chief Medical Officer and SVP Research & Development said: “We are very pleased to be recognised by the European Mediscience judging panel. This prestigious award is an additional motivation in our efforts to help patients and their families affected by rare, progressively debilitating diseases.”
The other companies shortlisted for the Mediscience “Emerging Star Award” were BioCartis NV, Oxford Nanopore Technologies Ltd and Sphere Medical Ltd.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Prosensa has selected clinical candidates for two more compounds for the treatment of Duchenne muscular dystrophy (DMD) and has been granted orphan drug designation for two additional DMD compounds in its pipeline.Prosensa identified suitable oligonucleotide candidates for PRO052 and PRO055 ... more
Prosensa wins “Emerging Star Award” at the European Mediscience Awards
Prosensa has won the Emerging Star accolade at the European Mediscience Awards. The European Mediscience Awards is the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe recognising achievements in the life sciences industry. Col ... more
Prosensa announced that it has received an innovation credit of up to €5m from AgentschapNL, a subsidiary of the Dutch Ministry of Economic Affairs, Agriculture and Innovation, to support further development of a series of preclinical compounds for the treatment of Myotonic Dystrophy type 1 ... more
Prosensa is a Dutch biopharmaceutical company dedicated to the development of RNA-based therapeutics targeting diseases with unmet medical needs, in particular neuromuscular disorders. Prosensa's drug development is based upon a unique and proprietary technology platform involving 'exon ski ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
